Market research
ALPHA.PA Pharnext SA
PA EUR Healthcare
Latest close
As of 16 Mar 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3K
- P/E ratio
- Not available
- Analyst target
- 12500
- Dividend yield
- Not available
- Beta
- -310.12
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR001400BV89
- Market cap
- 3K
- P/E ratio
- Not available
- Analyst target
- 12500
- Dividend yield
- Not available
- Beta
- -310.12
About
About Pharnext SA
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Research context
Pharnext SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALPHA.PA discussion.
5 years, 6 months ago
Pharnext SA is currently in a long term downtrend where the price is trading 62.7% below its 200 day moving average.
From a valuation standpoint, the stock is 209.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 845.9.
Based on the above factors, Pharnext SA gets an overall score of 0/5.